Abstract
Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
CD36 Antigens / metabolism
-
Cell Line, Tumor
-
Cisplatin / pharmacology
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
HEK293 Cells
-
Humans
-
Organoplatinum Compounds / pharmacology*
-
Ovarian Neoplasms / drug therapy*
-
Prodrugs / pharmacology*
Substances
-
Antineoplastic Agents
-
CD36 Antigens
-
CD36 protein, human
-
Organoplatinum Compounds
-
Prodrugs
-
Cisplatin